Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA To Public: Help Us Streamline Our Regs

Executive Summary

The agency is calling on all regulated industry and the public in general to recommend regulations that should be withdrawn, modified or replaced in line with President Trump's executive order from earlier this year to remove two regulations for every new one implemented.

You may also be interested in...

OMB: US FDA Has Withdrawn At least 10 Regulations In Response To Trump 2-for-1 Order

Following several executive orders from the president intended to remove regulations from the federal books, the White House tells Medtech Insight it has already pulled multiple rules from FDA and other agencies – and that number may still grow by the time the Office of Management and Budget has completed an agency-wide review.

Gottlieb Wants More Systematic Updates Of Regulations

The US FDA commissioner says the agency has gone through sporadic reviews of regulations, but he would like to see a more systematic process to continuously evaluate whether regulations should be modified or withdrawn.

Trump's Two-For-One Reg Order Needs Agency Interpretation, Medtech Reg Experts Say

For the most part, industry experts and lobbyists say they still have questions about President Trump's latest executive order, which requires agencies to rescind two regulations for every one rule that is implemented. With key leadership positions at HHS and FDA still unfilled, some say they are taking a wait-and-see approach before concluding how the order will be interpreted.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts